Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Kiadis Pharma    KDS   NL0011323407

KIADIS PHARMA

(KDS)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
8.76(c) 8.78(c) 8.89(c) 8.71(c) 8.84(c) Last
125 267 170 785 117 834 151 546 109 614 Volume
-1.68% +0.23% +1.25% -2.02% +1.49% Change
More quotes
Financials (EUR)
Sales 2018 -
EBIT 2018 -22,2 M
Net income 2018 -23,8 M
Finance 2018 4,30 M
Yield 2018 -
Sales 2019 2,42 M
EBIT 2019 -24,7 M
Net income 2019 -28,6 M
Finance 2019 12,4 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 83,9x
Capitalization 215 M
More Financials
Company
Kiadis Pharma specializes in the research and development of cellular immunotherapy products for the treatment of terminal-phase blood cancer. At the end of 2017, the group had a portfolio of 2 products in phase III of clinical development (ATIR101; treatment of acute leukemia and ATIR201;... 
More about the company
Surperformance© ratings of Kiadis Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on KIADIS PHARMA
02/15KIADIS PHARMA : Notice of Extraordinary General Meeting of Shareholders
GL
02/12KIADIS PHARMA : to participate in a panel at Innovation for Health 2019
AQ
02/11KIADIS PHARMA : to participate in a panel at Innovation for Health 2019
GL
02/05Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer
AQ
02/04KIADIS PHARMA : appoints Dr. Robert Friesen as Chief Scientific Officer
AQ
01/07Flurry of management moves on eve of JPM
AQ
01/04KIADIS PHARMA : expands presence in the United States
GL
01/03KIADIS PHARMA : to present at Biotech Showcase 2019
GL
2018KIADIS PHARMA : to present at upcoming investor conferences in November 2018
GL
2018KIADIS PHARMA : strengthens core team with three senior appointments
AQ
More news
Analyst Recommendations on KIADIS PHARMA
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart KIADIS PHARMA
Duration : Period :
Kiadis Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KIADIS PHARMA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 19,9 €
Spread / Average Target 125%
EPS Revisions
Managers
NameTitle
Arthur K. Lahr Chief Executive Officer
Mark A. Wegter Chairman-Supervisory Board
Jan Feijen Chief Operations Officer
Scott A. Holmes Chief Financial Officer
Andrew S. Sandler Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
KIADIS PHARMA15.86%243
IQVIA HOLDINGS INC11.13%28 377
CELLTRION, INC.--.--%23 803
LONZA GROUP14.80%21 653
INCYTE CORPORATION31.18%17 908
SEATTLE GENETICS, INC.17.42%11 477